CONCORD, Mass., Oct. 25, 2017 /PRNewswire/ -- Alopexx Vaccine LLC today announced that it has completed a Phase
"We are very encouraged by these early clinical data demonstrating the safety, tolerability and initial indications of clinical activity of AV0328 in humans," said Hal Landy, M.D., Chief Medical Officer at Alopexx. "We look forward to further evaluating AV0328 against a breadth of infections caused by PNAG-expressing pathogens, including serious soft-tissue infections caused by methicillin-resistant S. aureus (MRSA), pneumonia, meningitis, tuberculosis and sexually transmitted diseases, including those caused by antibiotic-resistant organisms."
"Our modified, synthetic vaccine that targets natural PNAG expressed on the surface of most pathogenic bacteria, as well as important eukaryotic pathogens like malaria and numerous fungi, could represent a new paradigm for disease prevention by inducing protection against a large number of infectious agents, including those manifesting high levels of antibiotic resistance" Gerald B. Pier, Professor of Medicine, Harvard Medical School, Microbiologist, Brigham and Women's Hospital.
About the Phase 1 Clinical StudyThe Phase 1 clinical study was designed to evaluate the safety, tolerability, pharmacodynamics (PD) and preliminary efficacy of AV0328 in 16 healthy volunteers across four dosing cohorts ranging from 15 to 150 mg. PD was assessed by measuring the increase and time course of serum titers against PNAG and complement binding (C1q deposition) activity. Clinical efficacy was assessed by measuring killing of PNAG-expressing pathogens by subject sera in vitro.
AV0328 was safe and well-tolerated in this study with only minor and transient injection site reactions observed in each dose group. At the two highest doses (75 mg and 150 mg), clear increases were noted in antibody titers against PNAG, as well as a positive indication of protective immunity, as measured by complement activation and binding to the PNAG antigen. In addition, robust bactericidal killing of N. gonorrhea, including antibiotic-resistant strains, and N. meningitidis (serogroups A, B, C, W, Y), as well as opsonic killing of S. pneumoniae, multi-drug resistant Klebsiella pneumonia, colistin and multi-drug resistant strains of E. coli and S. aureus, including MRSA clinical isolates, was observed.
About AV0328AV0328 is a synthetic pentameric oligosaccharide of b-1-6-linked D-glucosamine sugars conjugated to tetanus toxoid that elicits a protective antibody response against a large number of microbial pathogens associated with infections. PNAG, which is expressed on the surface of various bacteria, fungi and protozoan organisms, has been shown to be a critical factor in the virulence of many pathogens. In its natural state, PNAG has a profound ability to avoid eliciting an effective immune response. Bacterial strains that lose the ability to produce PNAG generally have a significantly reduced ability to cause infections. The fact that so many pathogens express PNAG suggests that it is a critical evolutionary feature for both microbial survival and for evading the mammalian immune system. A vaccine that effectively overcomes immune evasion to elicit antibodies that kill PNAG-producing pathogens could provide protection against not just individual strains or even an entire species of a pathogen, but against a wide array of serious microbial infectious agents.
About Alopexx Vaccine LLCAlopexx Vaccine LLC, part of the Alopexx Enterprises portfolio of companies, specializes in the development of vaccines against a range of pathogens and infections. For more information please visit www.Alopexx.com.
Contacts:Christine de los Reyes(Business Development)firstname.lastname@example.org 917-319-4915
Gina Nugent, Nugent Communications(Investors and Media)email@example.com
View original content:http://www.prnewswire.com/news-releases/alopexx-completes-first-in-man-trial-of-its-novel-broad-spectrum-anti-microbial-vaccine-300542366.html
SOURCE Alopexx Vaccine LLC
Subscribe to our Free Newsletters!
Abortion pills are used in the first trimester to terminate pregnancy. Women should be aware of ...
Tea tree oil is an essential oil derived from the leaves of the Melaleuca alternifolia plant and ...
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...View All